MASLD and MASH medical management research

Medical research has advanced the understanding and management of Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease. Researchers led by the Mayo Clinic utilized computational modeling of data from over 4,600 patients to propose that MASLD should be treated as five distinct subtypes based on factors such as sex, BMI, and blood biomarkers. This classification is intended to improve clinical assessment and allow for earlier intervention before severe damage like cirrhosis occurs.

Clinical guidance emphasizes that lifestyle modifications remain the foundation of treatment for both MASLD and Metabolic Dysfunction Associated Steatohepatitis (MASH). Experts recommend a Mediterranean-style diet and a weight loss of 7% to 10% to effectively address inflammation or fibrosis. Physical activity, including both aerobic and resistance exercise, is considered essential.

To ensure long-term success, experts suggest that patients require ongoing dietary support rather than single consultations. Additionally, clinicians are advised to monitor alcohol consumption via PEth testing to ensure accurate treatment assessments and to use consistent imaging platforms when evaluating the efficacy of pharmacological treatments such as resmetirom or semaglutide.